Counterfeit drugs pose growing health threat

Traynor, Kate
November 2010
American Journal of Health-System Pharmacy;11/15/2010, Vol. 67 Issue 22, p1896
Academic Journal
Information on several issues discussed at a symposium sponsored by the Partnership for Safe Medicines (PSM) on counterfeit medications held in Washington, D.C. on October 8, 2010 is presented. Topics include counterfeit medicines, proliferation of internet sites that sell counterfeit medicine, and development of risk models. The symposium features speakers including Margaret Hamburg of U.S. Food and Drug Administration (FDA), Nancy Kennedy, and Jeffrey Gren of U.S. Department of Commerce.


Related Articles

  • HOW DERMS HELP KNOCK OUT MARKET IMITATORS. Hilton, Lisette // Dermatology Times;Aug2013, Vol. 34 Issue 8, p1 

    The article discusses the role by dermatologists in an effort to combat drug counterfeiting in the U.S. as of 2013. According to Food and Drug Administration (FDA) Center for Drug Evaluation and Research regulatory counsel Karen Rothschild, medical practitioners should be wary about using drugs...

  • Cracking down on HEALTH FRAUD. Meadows, Michelle // FDA Consumer;Nov/Dec2006, Vol. 40 Issue 6, p16 

    The article reports on the action taken by the U.S. Food and Drug Administration to prevent health fraud. On April 19, 2006, the Federal Trade Commission led a massive Hispanic Multimedia Surf to identify potentially fraudulent advertising aimed at Spanish-speaking consumers. More than 160...

  • Call for political action to address continuing drug shortages. Lynas, Kathie // Canadian Pharmacists Journal (Allen Press Publishing Services In;Jan2012, Vol. 145 Issue 1, p6 

    Information on topics discussed at the roundtable hosted by Liberal Health Critic Dr. Hedy Fry and Liberal colleagues from the U.S. House of Commons and Senate, held in Ottawa, Ontario on November 24, 2011 is presented. Topics include issues on Canada's drug shortage and the lack of proactive...

  • FDA alerts clinicians about fake Botox.  // Dermatology Times;Feb2013, Vol. 34 Issue 2, p21 

    The article reports on the alerts issued by the U.S. Food and Drug Administration to more than 350 medical practices that may have purchased unapproved versions of onabotulinumtoxin A sent by foreign suppliers as distributors owned by Canada Drugs may have sent the unapproved neurotoxin products...

  • RISKY Business. Hilton, Lisette // Dermatology Times;Aug2013, Vol. 34 Issue 8, p26 

    The article presents a panel discussion on the counterfeit market held at the Vegas Cosmetic Surgery and Aesthetic Dermatology meeting in Las Vegas, Nevada in 2013. The panelists including dermatologist Amy Taub, plastic surgeon Michael Perski and dermatologist Rebecca Fitzgerald were asked...

  • Sick of mean cuisine. Spake, Amanda // U.S. News & World Report;09/14/98, Vol. 125 Issue 10, p28 

    Describes the work of the United States Food and Drug Administration (FDA) to test imported foods. Problem of bribery of food inspectors; Efforts at borders to evade inspections; Cases of foodborne illnesses in the US; Role of the FDA in inspections; Evading food controls through food...

  • US agencies policing Internet for health care fraud. Sullivan, Patrick // CMAJ: Canadian Medical Association Journal;10/16/2001, Vol. 165 Issue 8, p1083 

    Focuses on the actions taken by the United States Federal Trade Commission (FTC), U.S. Food and Drug Administration (FDA) and Health Canada to prevent health care fraud and misinformation over the Internet. How to report complaints.

  • Shuren to Congress: cuts under budget sequester 'are killing us'. McCARTY, MARK // Medical Device Daily;11/18/2013, Vol. 17 Issue 223, p1 

    The article reports on the feedback given by Jeff Shuren, director of the device center at the Food and Drug Administration (FDA), regarding the impact of the budget sequester on their vital programs. It presents statistics from the Congressional Budget Office pertaining to deficit in fiscal...

  • NEXT STEPS. Serebrov, Mari // BioWorld Today;2/6/2014, Vol. 25 Issue 25, p9 

    The article reports on the projected submission by the World Health Organization International Nonpropietary Names (WHO INN) Expert Group of a report to the Food and Drug Administration (FDA) on guidance on a biosimilar naming structure on March 1, 2014.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics